<DOC>
	<DOCNO>NCT01039688</DOCNO>
	<brief_summary>This study design compare effectiveness experimental drug , CP-690,550 , methotrexate prevent joint damage improve symptom rheumatoid arthritis . This study also compare safety CP-690,550 methotrexate .</brief_summary>
	<brief_title>Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug , CP-690,550 , To Methotrexate ( MTX ) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adults moderate severe RA ( Rheumatoid Arthritis ) treat methotrexate . Diagnosis RA base American College Rheumatology 1987 revise criterion . Active disease define &gt; =6 tender painful joint motion &gt; = 6 joint swell ; either erythrocyte sedimentation rate ( ESR ) &gt; 28 mm Creactive protein ( CRP ) concentration &gt; 7 mg/dL Blood dyscrasia include confirm : Hemoglobin &lt; 9 g/dL Hematocrit &lt; 30 % ; White blood cell count &lt; 3.0 x 109/L ; Absolute neutrophil count &lt; 1.2 x 109/L ; Platelet count &lt; 100 x 109/L History rheumatic autoimmune disease Sjogren 's syndrome No malignancy history malignancy History infection require hospitalization , parenteral antimicrobial therapy , otherwise judge clinically significant investigator , within 6 month prior first dose study drug No chronic liver disease , recent active hepatitis contraindication methotrexate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>oral JAK inhibitor</keyword>
	<keyword>MTX</keyword>
	<keyword>DMARD</keyword>
	<keyword>clinical trial</keyword>
	<keyword>joint disease</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>anti-Inflammatory agent</keyword>
	<keyword>rheumatic disease</keyword>
</DOC>